<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793307</url>
  </required_header>
  <id_info>
    <org_study_id>JLJY-GC301-IOPD-001</org_study_id>
    <nct_id>NCT05793307</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug</brief_title>
  <official_title>A Multi-centered, Single Arm, Open Labeled, Study to Evaluate the Safety and Efficacy of an Adeno-associated Virus Vector Expressing the Human Acid Alpha-glucosidase (GAA) Transgene Intravenous Injection in Patients With Infantile-onset Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneCradle Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeneCradle Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the safety and effectiveness of GC301&#xD;
      adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA)&#xD;
      as potential gene therapy for Pompe disease. Patients diagnosed with infantile-onset Pompe&#xD;
      disease who are younger than 6 months old will be studied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability over time</measure>
    <time_frame>52 weeks</time_frame>
    <description>Frequency of adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients treated with GC301 who are alive</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients treated w/ GC301 who were alive and free of ventilator support</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline Left Ventricular Mass (LVM) annd LVMI (LVM index)</measure>
    <time_frame>26 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline creatine kinase (CK), CK-MB, Troponin I, B-Type Natriuretic Peptide (BNP)</measure>
    <time_frame>26 and 52 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline glycogen content in muscle tissue</measure>
    <time_frame>26 and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline acid alpha-glucosidase (GAA) enzyme in muscle and blood</measure>
    <time_frame>26 and 52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in patient's motor function</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the changes in patient's mobility and physical ability using Hammersmith Infant Neurological Examination (HINE) scores</description>
  </other_outcome>
  <other_outcome>
    <measure>The viral load of adeno-associated virus (AAV) vector</measure>
    <time_frame>At multiple time points from pre-dose through up to 1 years post-dose</time_frame>
    <description>To assess the change of AAV vector copy numbers within 52 weeks after administration.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Pompe Disease Infantile-Onset</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous administration of GC301 at a dose of 8.0 x 10^13 vector genomes per kilogram body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous administration of GC301 at a dose of 1.2 x 10^14 vector genomes per kilogram body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous administration of GC301 at a dose of 1.8 x 10^14 vector genomes per kilogram body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>GC301</intervention_name>
    <description>GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 6 months&#xD;
&#xD;
          -  Patient has diagnosis of infantile onset Pompe disease&#xD;
&#xD;
          -  The patient's legal guardian(s) must be able to understand the purpose and risks of&#xD;
             the study and voluntarily provide signed and dated informed consent prior to any&#xD;
             study-related procedures being performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Left ventricle ejection fraction (LVEF) &lt; 40%;&#xD;
&#xD;
          -  Patient who has AAV9 neutralizing antibody titer ≥ 1:100；&#xD;
&#xD;
          -  Patient who has received enzyme replacement therapy (ERT) more than twice;&#xD;
&#xD;
          -  Patient who has respiratory dysfunction before enrollment, including the blood oxygen&#xD;
             (O2) saturation level &lt; 90%, or the partial pressure of carbon dioxide (PCO2) in&#xD;
             venous blood &gt; 55 mmHg, or PCO2 in arterial blood &gt; 40 mmHg;&#xD;
&#xD;
          -  Patient who has laboratory abnormalities of: creatinine &gt; Upper Limit of Normal (ULN),&#xD;
             hemoglobin &lt; 90 g/L;&#xD;
&#xD;
          -  Patient with congenital organ absence;&#xD;
&#xD;
          -  Patient with a history of glucocorticoid allergy;&#xD;
&#xD;
          -  Patient who is positive for human immunodeficiency (HIV) antibody, hepatitis B surface&#xD;
             antigen, hepatitis C antibody, or treponema pallidum antibody;&#xD;
&#xD;
          -  Patient who has participated in a previous gene therapy research trial;&#xD;
&#xD;
          -  Patient who has any concurrent clinically significant major disease or any other&#xD;
             condition that, in the opinion of the investigator, makes the subject unsuitable for&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>GeneCradle, Inc. China</last_name>
    <phone>86-13501380583</phone>
    <email>ind@bj-genecradle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Juan Ding</last_name>
    </contact>
    <investigator>
      <last_name>Zhengqing Qiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>301 Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xinting Liu</last_name>
    </contact>
    <investigator>
      <last_name>Guang Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central South University, Xiangya Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fang Zhou</last_name>
    </contact>
    <investigator>
      <last_name>Jing Peng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang University, School of Medicine, The Children's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yujia Wang</last_name>
    </contact>
    <investigator>
      <last_name>Yiying Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianjiang Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>April 2, 2023</last_update_submitted>
  <last_update_submitted_qc>April 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

